|
| 37522464 | The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies. | | 2023 |
| 36411076 | Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis. | Neurology: Neuroimmunology and NeuroInflammation | 2023 |
| 37753809 | A Genetic Risk Variant for Multiple Sclerosis Severity is Associated with Brain Atrophy. | Ann Neurol | 2023 |
| 37595878 | Preanalytic handling of clinical blood samples in assessing immunological proteins - Role of storage duration. | | 2023 |
| 37592277 | Cerebrospinal fluid levels of neuroinflammatory biomarkers are increased in athletes with persistent post-concussive symptoms following sports-related concussion. | | 2023 |
| 37903821 | Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. | | 2023 |
| 37702323 | Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury. | Clin Chem Lab Med | 2023 |
| 37558400 | Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy. | | 2023 |
| 37555492 | Improving the efficiency of clinical trials in multiple sclerosis. | Mult Scler | 2023 |
| 37334257 | Systemic Capillary Leak Syndrome With Cerebral Involvement in a Expansion Carrier: Case Report and Review of the Literature. | | 2023 |
| 37146654 | Immunological protein profiling of first-episode psychosis patients identifies CSF and blood biomarkers correlating with disease severity. | | 2023 |
| 37271040 | CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance. | | 2023 |
| 37205225 | Neuroimaging findings in preclinical amyotrophic lateral sclerosis models-How well do they mimic the clinical phenotype? A systematic review. | | 2023 |
| 37076291 | Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. | J Neurol Neurosurg Psychiatry | 2023 |
| 36573731 | Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis. | Brain Behav | 2023 |
| 37073483 | Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. | | 2023 |
| 36634138 | Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. | Proc Natl Acad Sci U S A | 2023 |
| 37006328 | Infections among individuals with multiple sclerosis, Alzheimer's disease and Parkinson's disease. | Brain Commun | 2023 |
| 36945422 | Dilated Virchow-Robin Spaces are a Marker for Arterial Disease in Multiple Sclerosis. | | 2023 |
| 37253317 | Dilated Virchow-Robin spaces are a marker for arterial disease in multiple sclerosis. | | 2023 |
| 36745446 | Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. | JAMA Neurol | 2023 |
| 36539267 | Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study. | | 2023 |
| 36922859 | A highly challenging balance training intervention for people with multiple sclerosis: a feasibility trial. | | 2023 |
| 36603296 | Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort. | | 2023 |
| 35083815 | Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis. | Journal of Neuroimaging | 2022 |
| 36110394 | Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseases-A systematic review and meta-analysis. | Frontiers in Neurology | 2022 |
| 36242804 | Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. | Multiple Sclerosis and Related Disorders | 2022 |
| 36107840 | Hospital-treated infections in early- and mid-life and risk of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden. | PLoS Med | 2022 |
| 36106020 | RNA-sequencing and mass-spectrometry proteomic time-series analysis of T-cell differentiation identified multiple splice variants models that predicted validated protein biomarkers in inflammatory diseases. | Front Mol Biosci | 2022 |
| 35841908 | Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. | Lancet Neurology, The | 2022 |
| 36174259 | Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy controls. | Multiple Sclerosis and Related Disorders | 2022 |
| 36037752 | High-intensity resistance training in people with multiple sclerosis experiencing fatigue: A randomised controlled trial. | Multiple Sclerosis and Related Disorders | 2022 |
| 36347843 | T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression. | Nat Commun | 2022 |
| 35437089 | Low-dose rituximab should be used for treating MS in resource-limited settings: Yes. | Multiple Sclerosis Journal | 2022 |
| 35808856 | B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. | Eur J Neurol | 2022 |
| 35618883 | Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. | Molecular Psychiatry | 2022 |
| 36329007 | Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia. | Nat Commun | 2022 |
| 35993445 | COVID-19 clinical outcomes and DMT of MS patients and population-based controls. | Annals of Clinical and Translational Neurology | 2022 |
| 35607517 | Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study. | Brain, Behavior, and Immunity - Health | 2022 |
| 36121672 | Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. | JAMA Neurology | 2022 |
| 35665740 | Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients. | Translational Psychiatry | 2022 |
| 36570871 | Association between brain volume and disability over time in multiple sclerosis. | | 2022 |
| 34264143 | Risk of depression in multiple sclerosis across disease-modifying therapies. | Multiple Sclerosis Journal | 2022 |
| 35332517 | The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors. | Acta Anaesthesiologica Scandinavica | 2022 |
| 35287794 | Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis. | Elife | 2022 |
| 34852680 | ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study. | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | 2022 |
| 35158476 | Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. | Multiple Sclerosis and Related Disorders | 2022 |
| 34882037 | Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. | Multiple Sclerosis Journal | 2022 |
| 35262993 | Demyelinating events following anti-tumor necrosis factor alpha therapy: Rare but challenging to treat. | European Journal of Neurology | 2022 |
| 35196927 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. | Mult Scler | 2022 |